ストックスクリーナーアプリを入手
5.28
4.76%
0.24
アフターアワーズ：
5.35
0.07
+1.33%
前日終値:
$5.04
開ける：
$5.08
24時間の取引高:
1.65M
Relative Volume:
0.92
時価総額：
$1.08B
収益：
-
当期純損益:
$-118.84M
株価収益率:
-9.8802
EPS:
-0.5344
ネットキャッシュフロー:
$-101.06M
1週間 パフォーマンス:
+4.76%
1か月 パフォーマンス:
-9.59%
6か月 パフォーマンス:
+52.16%
1年 パフォーマンス:
+90.61%
1日の値動き範囲:
$4.90
$5.365
1週間の範囲:
$4.81
$5.365
52週間の値動き範囲:
$1.89
$7.005
Savara Inc Stock (SVRA) Company Profile
Compare SVRA vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
5.28 | 1.03B | 0 | -118.84M | -101.06M | -0.5344 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-08-15 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-05-29 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-12-20 | 開始されました | Wells Fargo | Overweight |
| 2024-11-13 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-02-15 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-11-07 | 開始されました | Guggenheim | Buy |
| 2023-05-16 | アップグレード | Jefferies | Hold → Buy |
| 2023-03-31 | ダウングレード | Jefferies | Buy → Hold |
| 2021-03-16 | 開始されました | Piper Sandler | Overweight |
| 2021-03-15 | 開始されました | Oppenheimer | Outperform |
| 2019-06-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-06-13 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | 再開されました | ROTH Capital | Neutral |
| 2018-01-03 | 開始されました | Ladenburg Thalmann | Buy |
| 2017-09-27 | 再開されました | ROTH Capital | Buy |
| 2017-09-22 | 開始されました | Jefferies | Buy |
| 2017-09-11 | 開始されました | JMP Securities | Mkt Outperform |
すべてを表示
Savara Inc (SVRA) 最新ニュース
Aug Update: Whats the fair value of Savara Inc stockMarket Growth Review & Verified Swing Trading Watchlist - baoquankhu1.vn
Savara (SVRA) to Release Earnings on Tuesday - MarketBeat
Savara’s MOLBREEVI BLA Receives FDA Priority Review - MSN
Savara reports 2025 results, advances MOLBREEVI toward approval - MSN
FDA to review Savara resubmitted Molbreevi BLA - MSN
Savara Reports 2025 Results, Advances MOLBREEVI Toward Approval - MyChesCo
Savara Inc devrait afficher une perte de 12 cents par actionEarnings AVANT-PAPIER - TradingView
Aug Big Picture: What is the Moat Score of Savara IncNew Guidance & Stock Market Timing Techniques - baoquankhu1.vn
Savara (SVRA) CFO exercises stock options and ends with 536,032 shares - Stock Titan
VR Adviser Adds Over 1 Million Savara Shares - AOL.com
Will Advancing MOLBREEVI and a New HQ Lease Change Savara's (SVRA) Narrative? - simplywall.st
Savara grants inducement equity awards to new employee - MSN
Weekly Earnings: Can Savara Inc withstand a market correctionGDP Growth & Proven Capital Preservation Tips - baoquankhu1.vn
FY2026 Earnings Estimate for Savara Issued By HC Wainwright - MarketBeat
Lifesci Capital Analysts Lift Earnings Estimates for Savara - MarketBeat
HC Wainwright Comments on Savara's Q1 Earnings (NASDAQ:SVRA) - MarketBeat
Savara says FDA review of MOLBREEVI to proceed without advisory committee - MSN
Savara Showcases Promising Phase 3 Trial Data for Molgramostim at ATS 2025 - MSN
Langhorne, PA Biotech Eyes Mid-2026 Molbreevi Launch - streetwisereports.com
Growth Report: Will Savara Inc announce a stock splitForecast Cut & High Accuracy Swing Entry Alerts - baoquankhu1.vn
H.C. Wainwright Maintains Buy on Savara Inc. (SVRA) March 2026 - Meyka
H.C. Wainwright reiterates Savara stock rating, $10 target By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Savara stock rating, $10 target - Investing.com
Savara receives FDA day 74 letter for autoimmune PAP drug By Investing.com - Investing.com Nigeria
Savara Inc. $SVRA Stake Cut by Farallon Capital Management LLC - MarketBeat
VR Adviser Increases Savara Inc. Holdings in Q4 2025News and Statistics - IndexBox
Savara Says FDA Review of MOLBREEVI to Proceed Without Advisory Committee - MyChesCo
SVRA SEC FilingsSavara Inc 10-K, 10-Q, 8-K Forms - Stock Titan
SVRASavara Inc Latest Stock News & Market Updates - Stock Titan
Savara (NASDAQ:SVRA) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Decoding Savara Inc (SVRA): A Strategic SWOT Insight - GuruFocus
Savara receives FDA priority review for rare lung disease drug By Investing.com - Investing.com South Africa
Savara Inc. 2025 Annual Report: MOLBREEVI Clinical Progress, Business Strategy, and Key Risk Factors - Minichart
Savara Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update - BioSpace
Savara (SVRA) Advances with MOLBREEVI, Boosting Financial Positi - GuruFocus
Savara Signs Long-Term Lease for New Headquarters - TipRanks
Savara (NASDAQ: SVRA) details new Yardley headquarters lease terms - Stock Titan
SVRA: Regulatory progress and robust cash position set the stage for a potential 2026 launch - TradingView
Savara receives FDA priority review for rare lung disease drug - Investing.com
Savara : Corporate Presentation - marketscreener.com
Earnings Flash (SVRA) Savara Posts Q4 Loss $0.13 a Share, vs. FactSet Est of $0.12 Loss - marketscreener.com
Savara Q4 net loss widens as expenses rise - TradingView
Savara 10-K: $0M Revenue, $0.00 EPS; $118.8M Net Loss - TradingView
SVRA: Net loss increased to $118.8M in 2025 as MOLBREEVI advanced toward FDA review and commercialization - TradingView
MOLBREEVI strategy and FDA Priority Review drive Savara (NASDAQ: SVRA) - Stock Titan
BRIEF-Savara Q4 Net Income USD -32.236 Million - TradingView
Rosalind Advisors Inc. Has $14.28 Million Position in Savara Inc. $SVRA - MarketBeat
Aug Shorts: Why is Savara Inc stock going down2026 Key Lessons & Intraday High Probability Alerts - baoquankhu1.vn
Savara Inc (SVRA) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):